Cross Country Healthcare INC 8-K filings

Cross Country Healthcare's stockholders have overwhelmingly approved the merger agreement with KL Criss Cross Intermediate, LLC, paving the way for the company to be delisted from NASDAQ.

Cross Country Healthcare, Inc. files an 8-K to supplement its proxy statement regarding a pending merger, addressing shareholder litigation and providing updated financial analysis details.

Cross Country Healthcare announced first quarter 2026 financial results, reporting a net loss but highlighting sequential revenue growth and strategic wins.

Cross Country Healthcare, Inc. announced a definitive agreement to be acquired by Knox Lane in an all-cash transaction valued at $437 million, offering a significant premium to its shareholders.

Cross Country Healthcare, Inc. has scheduled its first quarter 2026 earnings conference call for May 7, 2026.

Cross Country Healthcare appoints Amiee Hawkins as Chief Operating Officer effective March 28, 2026, with no changes to her compensation.

Cross Country Healthcare Inc. announced the departure of its Chief Information Officer, Phil Noe, who will receive severance and provide transitional consulting services.

Cross Country Healthcare, Inc. announced significant net losses for the fourth quarter and full year ended December 31, 2025, alongside revenue declines, despite positive cash flow and a strong balance sheet.

Cross Country Healthcare announced its participation in two upcoming investor conferences in March 2026, where executives will hold one-on-one meetings.

Cross Country Healthcare will host its fourth quarter and full year 2025 earnings conference call on March 4, 2026, following the release of financial results.

Cross Country Healthcare, Inc. announced its 2026 Annual Meeting will be held on May 11, 2026, and revised deadlines for stockholder proposals and director nominations due to the advanced meeting date.

Cross Country Healthcare, Inc. filed an amendment to its 8-K report, outlining the comprehensive compensation package for its President and CEO, Kevin C. Clark, including salary, bonuses, and equity awards.

Cross Country Healthcare announced the departure of CEO John A. Martins and the immediate appointment of co-founder and Chairman Kevin C. Clark as his successor, effective December 14, 2025.

Cross Country Healthcare, Inc. stockholders approved the election of seven directors, ratified Deloitte & Touche as its auditor, and endorsed executive compensation at its Annual Meeting on December 9, 2025.

Cross Country Healthcare's merger agreement with Aya Healthcare has been terminated, resulting in a $20 million termination fee and immediate share repurchases.

Cross Country Healthcare announced third quarter 2025 financial results, reporting a revenue decline and net loss, while providing an update on its pending merger with Aya Healthcare which faces delays due to a government shutdown.

Cross Country Healthcare, Inc. announced its 2025 Annual Meeting of Stockholders for December 9, 2025, contingent on the completion of its merger with Aya Healthcare, Inc. in Q4 2025.

Cross Country Healthcare's merger agreement with Aya Holdings II Inc. has been automatically extended to December 3, 2025, as regulatory review continues.

Cross Country Healthcare reported a 19% year-over-year revenue decline in Q2 2025, with a net loss of $6.7 million, while confirming its merger with Aya Healthcare is expected to close in Q4.

Cross Country Healthcare reports a decrease in revenue and adjusted EBITDA for Q1 2025, while highlighting growth in Homecare and Physician Staffing.

Cross Country Healthcare announced its fourth quarter and full year 2024 financial results, showing revenue declines but highlighting growth in Physician and Homecare Staffing, while awaiting the closing of its merger with Aya Healthcare.

Cross Country Healthcare stockholders have approved the proposed acquisition by Aya Healthcare, expected to close in the second half of 2025.

Cross Country Healthcare's merger with Aya Healthcare is now expected to close in the second half of 2025 due to a second request for additional information from the U.S. Federal Trade Commission (FTC).

Aya Healthcare will acquire Cross Country Healthcare for $18.61 per share in cash, valuing the transaction at approximately $615 million.

Cross Country Healthcare announced its third quarter 2024 financial results, showing a mix of revenue declines and margin pressures alongside growth in specific segments and a strong balance sheet.

Cross Country Healthcare, Inc. will attend the UBS Global Healthcare Conference in November for investor meetings.

Cross Country Healthcare will host a conference call on November 6, 2024, to discuss its third quarter 2024 financial results.

Cross Country Healthcare will participate in the Morgan Stanley and Barrington Research investor conferences in September 2024.

Cross Country Healthcare's second quarter results show a significant year-over-year revenue decline, but some positive signs in physician staffing and cash flow.

Cross Country Healthcare amended its ABL Credit Agreement to exclude certain share repurchases from the fixed charge coverage ratio calculation, providing more financial flexibility.